A detailed history of New England Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, New England Asset Management Inc holds 25,165 shares of ABBV stock, worth $4.21 Million. This represents 0.74% of its overall portfolio holdings.

Number of Shares
25,165
Previous 31,740 20.72%
Holding current value
$4.21 Million
Previous $4.92 Million 6.83%
% of portfolio
0.74%
Previous 0.83%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $1.05 Million - $1.2 Million
-6,575 Reduced 20.72%
25,165 $4.58 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $2.63 Million - $2.96 Million
-19,100 Reduced 37.57%
31,740 $4.92 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $260,500 - $301,567
-1,950 Reduced 3.69%
50,840 $7.58 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $355,017 - $408,855
-2,455 Reduced 4.44%
52,790 $8.41 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $1.32 Million - $1.58 Million
9,550 Added 20.9%
55,245 $8.93 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $3.98 Million - $4.56 Million
-29,650 Reduced 39.35%
45,695 $6.13 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $75,691 - $96,228
550 Added 0.74%
75,345 $11.5 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $85,787 - $106,437
650 Added 0.88%
74,795 $12.1 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $794,982 - $1.01 Million
7,400 Added 11.09%
74,145 $10 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $287,280 - $326,106
2,700 Added 4.22%
66,745 $7.2 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $231,462 - $257,862
2,200 Added 3.56%
64,045 $7.21 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $86,955 - $95,727
850 Added 1.39%
61,845 $6.69 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $124,759 - $168,438
1,550 Added 2.61%
60,995 $6.54 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $176,115 - $206,701
-2,050 Reduced 3.33%
59,445 $5.21 Million
Q2 2020

Aug 17, 2020

SELL
$73.37 - $98.18 $403,535 - $539,990
-5,500 Reduced 8.21%
61,495 $6.04 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $251,550 - $381,381
3,900 Added 6.18%
66,995 $5.1 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $82,949 - $103,787
-1,150 Reduced 1.79%
63,095 $5.59 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $629,800 - $757,200
10,000 Added 18.43%
64,245 $4.87 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $26,280 - $33,592
-400 Reduced 0.73%
54,245 $3.95 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $173,950 - $204,731
2,255 Added 4.3%
54,645 $4.4 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $155,700 - $192,020
2,000 Added 3.97%
52,390 $4.83 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $5,334 - $5,930
-60 Reduced 0.12%
50,390 $4.77 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $471,345 - $557,707
5,250 Added 11.62%
50,450 $4.67 Million
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $542,859 - $726,939
-5,900 Reduced 11.55%
45,200 $4.28 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $89,560 - $98,210
-1,000 Reduced 1.92%
51,100 $4.94 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $3.64 Million - $4.65 Million
52,100
52,100 $4.63 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track New England Asset Management Inc Portfolio

Follow New England Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New England Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on New England Asset Management Inc with notifications on news.